Â
Today we are watching…
1. Gilead Sciences (#gildsci)
Scientists at this front running biotech giant are working overtime to get a new coronavirus cure tested on humans before we’ve all been zombified, or before another company gets there first (equally scary outcomes for investors). Clinical trials for the priceless medicine are underway in Wuhan, ground zero of the outbreak, but this process usually takes years. Despite a regulatory FastTrack, the cost for Gilead to prove its drug is safe and effective is still tremendous. The good news is that Gilead invented the therapeutics market singlehandedly and built a $20 billion business on a portfolio of only nineteen drugs. Shares rose 8% in the belief of positive test results. Save the world, Gilead!
2. Ferrari (#race)
The Prancing Horse will pull the blanket off a range of new supercars this year, and investors are happy if the Tifosi are happy. Credit Suisse believes Ferrari is getting the most out of its mega-brand value by choosing high volume cars over exclusive one-offs, awarding the Italian company with a $205 price target. The firm is also ramping up lines of luxury watches and clothing. The company is revving up this morning to reveal the quarter’s earnings. The analyst consensus is for $1.02 in profit per share on revenues of $958 million.